IL4 and myocardial infarction: MSCs geneticallymodified to secrete interleukin-4 and -10 (IL-4 and IL-10) improvedtheir ability to reduce the progression of osteoarthritis in preclinicalstudies,11,12 while MSCs modified to overexpress and secretehepatocyte growth factor (HGF) improved their cell survival postimplantationand improved their ability to treat myocardial infarction in preclinicalstudies.13